Begonya Comin-Anduix

发表

A Clinical Microchip for Evaluation of Single Immune Cells Reveals High Functional Heterogeneity in Phenotypically Similar T Cells Nih Public Access Author Manuscript Design Rationale and Detection Limit of the Scbc Online Methods Microchip Fabrication On-chip Secretion Profiling Supplementary Mater

Rong Fan, Gabriel A Kwong, Antoni Ribas, 2022 .

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

Robert Damoiseaux, Antoni Ribas, Begonya Comin-Anduix, 2017, Cell reports.

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.

T. Graeber, A. Ribas, R. Damoiseaux, 2019, Cell reports.

Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction

Katie M. Campbell, Christopher A. Miller, Brian J. Stevenson, 2020, Cell.

Single-cell analysis resolves the cell state transition and signaling dynamics associated with melanoma drug-induced resistance

T. Graeber, J. Heath, A. Ribas, 2017, Proceedings of the National Academy of Sciences.

Intra–Lymph Node Prime-Boost Vaccination against Melan A and Tyrosinase for the Treatment of Metastatic Melanoma: Results of a Phase 1 Clinical Trial

S. Raman, A. Ribas, J. Weber, 2011, Clinical Cancer Research.

IND-Enabling Studies for a Clinical Trial to Genetically Program a Persistent Cancer-Targeted Immune System

K. Cornetta, D. Baltimore, A. Ribas, 2018, Clinical Cancer Research.

MHC-I-restricted melanoma antigen specific TCR-engineered human CD4+ T cells exhibit multifunctional effector and helper responses, in vitro.

A. Ribas, S. Rosenberg, U. Hegde, 2010, Clinical immunology.

Cells in the Absence of CD8-Positive Cells Enhanced Tumor Responses to Dendritic

J. Wargo, A. Ribas, W. McBride, 2013 .

Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells

J. Wargo, A. Ribas, L. Butterfield, 2005, Cancer Gene Therapy.

Enhanced Tumor Responses to Dendritic Cells in the Absence of CD8-Positive Cells1

J. Wargo, A. Ribas, L. Butterfield, 2004, The Journal of Immunology.

Role of Dendritic Cell Phenotype, Determinant Spreading, and Negative Costimulatory Blockade in Dendritic Cell-Based Melanoma Immunotherapy

J. Wargo, A. Ribas, L. Butterfield, 2004, Journal of immunotherapy.

Immunomodulation by imiquimod in patients with high-risk primary melanoma

A. Ribas, J. Economou, H. Vargas, 2011, The Journal of investigative dermatology.

Lentiviral vectors with CMV or MHCII promoters administered in vivo: immune reactivity versus persistence of expression.

Yan Cui, He-jing Wang, C. Sternini, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

T-Cell Responses to Survivin in Cancer Patients Undergoing Radiation Therapy

A. Debucquoy, K. Haustermans, A. Ribas, 2008, Clinical Cancer Research.

cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

P. Mischel, A. Ribas, R. Lo, 2011 .

Distinct immunological mechanisms of CTLA-4 and PD-1 blockade revealed by analyzing TCR usage in blood lymphocytes

R. Emerson, C. Harview, A. Ribas, 2014, Oncoimmunology.

HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression

A. Ribas, P. Lowenstein, K. Michelsen, 2009, PLoS medicine.

Innate resistance of PD-1 blockade through loss of function mutations in JAK resulting in inability to express PD-L1 upon interferon exposure

T. Graeber, A. Ribas, Helena Escuin-Ordinas, 2015, Journal of Immunotherapy for Cancer.

Antiestrogens in combination with immune checkpoint inhibitors in breast cancer immunotherapy

Gang Deng, Hsiao-Wang Chen, Begonya Comin-Anduix, 2019, The Journal of Steroid Biochemistry and Molecular Biology.

BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.

T. Graeber, A. Ribas, Stephen Mok, 2012, Cancer research.

Immunosensitization with a Bcl-2 small molecule inhibitor

A. Ribas, Stephen Mok, D. Vo, 2009, Cancer Immunology, Immunotherapy.

Adenovirus MART-1–engineered Autologous Dendritic Cell Vaccine for Metastatic Melanoma

A. Ribas, L. Butterfield, J. Economou, 2008, Journal of immunotherapy.

Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma

Antoni Ribas, Lidia Robert, Bjoern Titz, 2014, Clinical Cancer Research.

Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

T. Graeber, A. Ribas, R. Lo, 2014, Molecular Cancer.

COX‐2 inhibition prevents the appearance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors

T. Graeber, A. Ribas, A. Cochran, 2014, Molecular oncology.

Reversing Melanoma Cross-Resistance to BRAF and MEK Inhibitors by Co-Targeting the AKT/mTOR Pathway

P. Mischel, A. Ribas, R. Lo, 2011, PloS one.

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma

T. Graeber, A. Ribas, Helena Escuin-Ordinas, 2015, Molecular Cancer.

Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells.

Gabriel A Kwong, Ton N Schumacher, Antoni Ribas, 2009, Journal of the American Chemical Society.

CTLA4 blockade increases Th17 cells in patients with metastatic melanoma

A. Ribas, R. Koya, N. Attar, 2009, Journal of Translational Medicine.

Erratum to: Antitumor activity of the ERK inhibitor SCH722984 against BRAF mutant, NRAS mutant and wild-type melanoma

T. Graeber, A. Ribas, R. Lo, 2015, Molecular Cancer.

Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma

A. Ribas, L. Robert, D. Wong, 2014, Molecular Cancer.

Improved Localization of Glucose-6-phosphate Dehydrogenase Activity in Cells with 5-Cyano-2, 3-ditolyl-tetrazolium Chloride as Fluorescent Redox Dye Reveals its Cell Cycle-dependent Regulation

M. Cascante, J. van Marle, W. Frederiks, 2006, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

Combined treatment with dabrafenib and trametinib with immune-stimulating antibodies for BRAF mutant melanoma

A. Ribas, Stephen Mok, S. Hu-Lieskovan, 2015, Oncoimmunology.

Multifunctional T-cell analyses to study response and progression in adoptive cell transfer immunotherapy.

David Baltimore, Antoni Ribas, James R Heath, 2013, Cancer discovery.

Highlights of the society for immunotherapy of cancer (SITC) 27th annual meeting

F. Marincola, R. Puri, L. Zitvogel, 2013, Journal of Immunotherapy for Cancer.

A kinetic investigation of interacting, stimulated T cells identifies conditions for rapid functional enhancement, minimal phenotype differentiation, and improved adoptive cell transfer tumor eradication

J. Heath, D. Baltimore, A. Ribas, 2018, PloS one.

Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations

P. Mischel, A. Ribas, R. Lo, 2011, Journal of Translational Medicine.

A β-Camera Integrated with a Microfluidic Chip for Radioassays Based on Real-Time Imaging of Glycolysis in Small Cell Populations

Arion F Chatziioannou, Hsian-Rong Tseng, Antoni Ribas, 2011, The Journal of Nuclear Medicine.

Title Combination therapy with vemurafenib ( PLX 4032 / RG 7204 ) and metformin in melanoma cell lines with distinct driver mutations

P. Mischel, A. Ribas, R. Lo, 2011 .

Changes in Intratumoral Immune Cell Infiltrates, Foxp3 and Indoleamine 2, 3-Dioxygenase (IDO) Expression With the CTLA4 Blocking MAB CP-675,206

A. Ribas, J. Economou, J. Glaspy, 2006 .

Combinatorial effect of dabrafenib, trametinib, and adoptive cell transfer (ACT) in an immune-competent murine model of BRAFV600E mutant melanoma.

A. Ribas, Stephen Mok, S. Hu-Lieskovan, 2014 .

Consensus nomenclature for CD 8 T cell phenotypes in cancer

S. H. van der Burg, J. Blay, F. Marincola, 2015 .

A clinical microchip for evaluation of single immune cells reveals high functional heterogeneity in phenotypically similar T cells

J. Heath, A. Ribas, R. Fan, 2011, Nature Network Boston.

Modular nucleic acid assembled p/MHC microarrays for multiplexed sorting of antigen-specific T cells.

J. Heath, T. Schumacher, A. Ribas, 2009, Journal of the American Chemical Society.